Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Yкраїнський (UK)
Przejdź do strony domowej biblioteki Centralna Biblioteka Wojskowa Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaCentralna Biblioteka Wojskowa

Wyszukujesz frazę "Prostate cancer" wg kryterium: Temat

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-15 z 15
    Tytuł:
    Apalutamide as a therapeutic option in case of local failure in the nmCRPC
    Autorzy:
    Stankiewicz, Magdalena
    Powiązania:
    https://bibliotekanauki.pl/articles/22676730.pdf
    Data publikacji:
    2023-04-01
    Wydawca:
    Medical Education
    Tematy:
    prostate cancer
    castration resistance
    apalutamide
    Opis:
    Apalutamide is a non-steroidal selective androgen receptor inhibitor approved for the treatment of high-risk non-metastatic castration-resistant prostate cancer and metastatic hormone-sensitive prostate cancer. The paper describes a case of a patient diagnosed with prostate cancer with a long-term course of the disease. The patient was diagnosed with a non-metastatic castration-resistant stage 18 years after primary treatment. Systemic treatment with apalutamide was recommended. Initially, the treatment was carried out as part of the extended access to apalutamide program and from March 2022 as part of the B.56 drug program. The study presents the effectiveness and safety of the therapy in a 12-month follow-up period and discusses controversial aspects of the patient's previous treatments.
    Źródło:
    OncoReview; 2023, 13, 1; 13-19
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Time to treatment of prostate cancer patients
    Autorzy:
    Rucińska, Monika
    Osowiecka, Karolina
    Gałka, Szymon
    Środa, Radosław
    Wojciechowski, Piotr
    Sugajska, Anna
    Powiązania:
    https://bibliotekanauki.pl/articles/1035802.pdf
    Data publikacji:
    2018
    Wydawca:
    Medical Education
    Tematy:
    prostate cancer
    waiting for treatment
    Opis:
    Prostate cancer is one of the most common cancers in men. The incidence of prostate cancer increases systematically. The correlation between waiting time for oncological treatment and survival prognosis in prostate cancer is not clearly determined. The aim of the study was to estimate the waiting time from suspicion until prostate cancer diagnosis and treatment in Warmia and Mazury Voivodeship. Ninety-six consecutive prostate cancer patients treated with radical radiotherapy between November 2016 and June 2017 in the Department of Radiation Oncology of the Hospital of the Ministry of Internal Affairs with Warmia and Mazury Oncology Center in Olsztyn were included in the analysis. A questionnaire prepared especially for this study, and individual interviews with patients were used in the study. The obtained data was supplemented with medical records and hospital databases. In the case of twenty-nine men, the PSA concentration was measured due to urinary disorders, and the median time from symptoms until the first PSA test in that group was 168 days. The median time from PSA concentration > 4 ng/ml to biopsy of prostate cancer and start of treatment for all patients was 62 and 156 days, respectively. Hormone therapy was administered the quickest. A positive correlation was observed between the waiting time from histopathological confirmation of prostate cancer until treatment, and the distance from one’s place of residence to the oncological center (p < 0.05).
    Źródło:
    OncoReview; 2018, 8, 3; 86-93
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Prostate cancer in an elderly patient with a history of comorbidities
    Autorzy:
    Stryczyńska-Mirocha, Adriana
    Mirocha, Martyna
    Powiązania:
    https://bibliotekanauki.pl/articles/22676694.pdf
    Data publikacji:
    2023-03-31
    Wydawca:
    Medical Education
    Tematy:
    prostate cancer
    hormone therapy
    nmCRPC
    apalutamide
    Opis:
    Prostate cancer is the most common cancer in men in Poland. The choice of treatment method depends on many factors, including the stage of the disease, the patient's age, life expectancy, the presence of comorbidities and the general condition of the patient. Hormone therapy is one of the basic methods of prostate cancer treatment, both in adjuvant and palliative treatment. Castration-resistant prostate cancer is an incurable disease. However, the introduction of new hormonal drugs to therapy significantly extended the survival time of patients with relatively low harmfulness of therapy.
    Źródło:
    OncoReview; 2023, 13, 1; 3-5
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Apalutamide treatment of locally advanced prostate cancer
    Autorzy:
    Palasik, Maria
    Powiązania:
    https://bibliotekanauki.pl/articles/22676859.pdf
    Data publikacji:
    2023-03-31
    Wydawca:
    Medical Education
    Tematy:
    prostate cancer
    castration resistance
    hormonotherapy
    apalutamide
    Opis:
    Prostate cancer is most commonly diagnosed cancer in men. The choice of treatment method depends on many factors: the patient’s age, other patient’s diseases, psychophysical status and expected survival time. Hormonotherapy plays very important role in patients with no possible radical treatment. New therapies apply in patients with castration-resistant metastatic prostate cancer. First registered drug in patients with biochemical progression without metastases is apalutamide.
    Źródło:
    OncoReview; 2023, 13, 1; 31-32
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Triptorelin in androgen depravation therapy of advanced prostate cancer
    Autorzy:
    Kozikowski, Mieszko
    Dobruch, Jakub
    Powiązania:
    https://bibliotekanauki.pl/articles/1035670.pdf
    Data publikacji:
    2019
    Wydawca:
    Medical Education
    Tematy:
    advanced prostate cancer
    androgen depravation therapy
    triptorelin
    Opis:
    Triptorelin as the luteinizing hormone releasing hormone (LHRH) analogue has its own place among other available forms of androgen-depravation therapy (ADT) of locally advanced and metastatic prostate cancer (PCa). Nowadays, in times of development of new therapies in castration-resistant PCa, ADT remains the back bone therapy, which may be supplemented with one of novel drugs. The results of basic research indicate, that apart from the main mechanism of action based on lowering a testosterone concentration to the castration level, triptorelin may have a direct inhibitory effect on tumor cells. Formulations of tryptorelin are available to administer as 1-month, 3-months and 6-months sustained-release forms that may be given intramuscularly or subcutaneously. Constant concentration of triptoreline is maintained by using special microspheres in drug production. Pharmacokinetic and pharmacodynamic properties of particular forms were extensively tested, which allows for safe usage and retain of predictable and high efficacy. Indicators of effective ADT are fast reduction and maintenance of the state of castration. This phenomenon translates into a decrease of the prostate-specific antigen and longer survival. Triptorelin successfully meets these objectives based on a number of phase I–III studies. There is a noticeable lack of comparative studies on effectiveness of particular ADT forms. This may stem from an assumption, that all LHRH analogues demonstrate similar effectiveness because of the class effect. However, some evidence highlight significant differences in efficacy among these drugs. Triptorelin compares especially favourably, particularly as a drug reducing the testosterone level to the lower recommended values (< 20 ng/dl). Side effect profile during the therapy with triptorelin is largely the result of inhibition of the hypothalamic pituitary-testicular axis. Hormonal disturbances linked to hipoandrogenism cause changes in lipid metabolism and glucose tolerance, which may influence the cardiovascular risk. This article is a review of key reports regarding triptorelin and a summary of the role that triptorelin plays in contemporary ADT in advanced PCa.
    Źródło:
    OncoReview; 2019, 9, 4; 73-87
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Apalutamide in the treatment of a patient with non-metastatic castration-resistant prostate cancer
    Autorzy:
    Dziura, Robert
    Powiązania:
    https://bibliotekanauki.pl/articles/22676763.pdf
    Data publikacji:
    2023-03-31
    Wydawca:
    Medical Education
    Tematy:
    prostate cancer
    castration-resistant
    androgen receptor inhibitor
    Opis:
    The treatment of patients with prostate cancer, who do not qualify for the radical therapy is based on the use of surgical or pharmacological castration methods. The effectiveness of the so-called androgen deprivation tends to decrease over time. Even in the absence of distant metastases on imaging studies, the resistance for the hormonal castration may be developed. At this moment, the use of new generation androgen receptor inhibitors may reduce the risk of metastases or death. The paper presents a case report of a patient with prostate cancer without distant metastases who started therapy with apalutamide at the moment of developing re-sistance to the pharmacological castration.
    Źródło:
    OncoReview; 2023, 13, 1; 20-23
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Apalutamide as a new option for postponing metastatic disease in hormone -resistant patients with biochemical recurrence in prostate cancer
    Autorzy:
    Dąbek, Bartosz
    Powiązania:
    https://bibliotekanauki.pl/articles/22676825.pdf
    Data publikacji:
    2023-04-04
    Wydawca:
    Medical Education
    Tematy:
    non-metastatic castration-resistant prostate cancer
    apalutamide
    Opis:
    Treatment of non-metastatic castration-resistant prostate cancer is a radically new option for cancer patients. Novel anti-hormonal therapy not only improves metastasis free survival but overall survival times and positively impacts quality of life. This case shows how apalutamide lowered tPSA level and postponed metastatic disease.
    Źródło:
    OncoReview; 2023, 13, 1; 24-26
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    „Iron Heart”: Reversible Cause of Dilated Cardiomyopathy Secondary to Cardiac Toxicity in Elderly Patient with Myelodysplastic Syndrome
    Autorzy:
    Martin-Garcia, Ana
    Alonso Fernandez de Gatta, Marta
    Diez-Campelo, María
    Martín-García, Agustín C.
    Barreiro Pérez, Manuel
    Diaz-Pelaez, Elena
    López Cadenas, Félix
    Sanchez, Pedro L.
    Powiązania:
    https://bibliotekanauki.pl/articles/1035672.pdf
    Data publikacji:
    2019
    Wydawca:
    Medical Education
    Tematy:
    advanced prostate cancer
    androgen depravation therapy
    triptorelin
    Opis:
    Triptorelin as the luteinizing hormone releasing hormone (LHRH) analogue has its own place among other available forms of androgen-depravation therapy (ADT) of locally advanced and metastatic prostate cancer (PCa). Nowadays, in times of development of new therapies in castration-resistant PCa, ADT remains the back bone therapy, which may be supplemented with one of novel drugs. The results of basic research indicate, that apart from the main mechanism of action based on lowering a testosterone concentration to the castration level, triptorelin may have a direct inhibitory effect on tumor cells. Formulations of tryptorelin are available to administer as 1-month, 3-months and 6-months sustained-release forms that may be given intramuscularly or subcutaneously. Constant concentration of triptoreline is maintained by using special microspheres in drug production. Pharmacokinetic and pharmacodynamic properties of particular forms were extensively tested, which allows for safe usage and retain of predictable and high efficacy. Indicators of effective ADT are fast reduction and maintenance of the state of castration. This phenomenon translates into a decrease of the prostate-specific antigen and longer survival. Triptorelin successfully meets these objectives based on a number of phase I–III studies. There is a noticeable lack of comparative studies on effectiveness of particular ADT forms. This may stem from an assumption, that all LHRH analogues demonstrate similar effectiveness because of the class effect. However, some evidence highlight significant differences in efficacy among these drugs. Triptorelin compares especially favourably, particularly as a drug reducing the testosterone level to the lower recommended values (< 20 ng/dl). Side effect profile during the therapy with triptorelin is largely the result of inhibition of the hypothalamic- pituitary-testicular axis. Hormonal disturbances linked to hipoandrogenism cause changes in lipid metabolism and glucose tolerance, which may influence the cardiovascular risk. This article is a review of key reports regarding triptorelin and a summary of the role that triptorelin plays in contemporary ADT in advanced PCa.
    Źródło:
    OncoReview; 2019, 9, 4; 88-91
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Apalutamide - 10 clinically important facts
    Autorzy:
    Juszczak, Kajetan
    Drewa, Tomasz
    Powiązania:
    https://bibliotekanauki.pl/articles/2047224.pdf
    Data publikacji:
    2021-09-30
    Wydawca:
    Medical Education
    Tematy:
    apalutamide
    prostate cancer
    nonmetastatic
    metastatic
    CRPC
    CSPC
    Opis:
    Apalutamide belongs to the ARTA group. This drug is a new generation selective androgen receptor inhibitor. Patients with prostate cancer develop resistance to castration testosterone levels over time during hormone therapy. Therefore, it is necessary to consider additional therapeutic options based on drugs from the ARTA group. Apalutamide is used in the treatment of patients with non-metastatic as well as metastatic prostate cancer. This article presents the most important clinical facts about apalutamide.
    Źródło:
    OncoReview; 2021, 11, 3; 85-88
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    The site of apalutamide in the treatment of prostate cancer
    Autorzy:
    Juszczak, Kajetan
    Drewa, Tomasz
    Powiązania:
    https://bibliotekanauki.pl/articles/2047808.pdf
    Data publikacji:
    2021-09-22
    Wydawca:
    Medical Education
    Tematy:
    apalutamide
    prostate cancer
    nonmetastatic
    metastatic
    CRPC
    CSPC
    Opis:
    Apalutamide belongs to the ARTA group. This drug is a new generation selective androgen receptor inhibitor. Patients with prostate cancer develop resistance to castration testosterone levels over time during hormone therapy. Therefore, it is necessary to consider additional therapeutic options based on drugs from the ARTA group. The article presents the role of apalutamide in the treatment of prostate cancer and its effectiveness. Moreover, attention was drawn to the need for close cooperation between the urologist and the oncologist in order to optimize the treatment of a patient with progressive prostate cancer.
    Źródło:
    OncoReview; 2021, 11, 4; 120-122
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Cardiovascular complications during the treatment of castration-resistant prostate cancer with the use of modern antiandrogens: abiraterone acetate and enzalutamide
    Autorzy:
    Grabysa, Radosław
    Chmielewska, Agnieszka
    Powiązania:
    https://bibliotekanauki.pl/articles/2047222.pdf
    Data publikacji:
    2021-09-13
    Wydawca:
    Medical Education
    Tematy:
    abiraterone acetate
    enzalutamide
    castration resistant prostate cancer
    cardiovascular
    Opis:
    Modern antiandrogens: abiraterone acetate (inhibitor of CYP17 cytochrome) and enzalutamide (irreversible inhibitor of androgen receptor) are the drugs that are increasingly often administered in treatment of castration-resistant prostate cancer. Despite their clinical efficacy, especially in terms of prolonged survival and improved quality of life of patients, they pose of problem for a practicing oncologist such as possible cardiovascular complications (particularly arterial hypertension), which may lead to the cessation of this form of therapy. This article provides a brief overview of the mechanisms responsible for the above complications, including practical recommendations in the event such complications arise. A simple scheme of action for control of cardiovascular risk factors has been presented, which can improve the prognosis in this population of patients.
    Źródło:
    OncoReview; 2021, 11, 3; 61-67
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Abiraterone acetate - 10 clinically relevant facts
    Autorzy:
    Żołnierek, Jakub
    Powiązania:
    https://bibliotekanauki.pl/articles/2047213.pdf
    Data publikacji:
    2021-09-30
    Wydawca:
    Medical Education
    Tematy:
    prostate cancer
    systemic therapy
    hormone therapy
    abiraterone acetate
    Opis:
    Prostate cancer is one of the most frequently diagnosed cancers in men. Number of newly diagnosed cases is increasing due to several factors and the most important ones seem to be: population ageing and more sensitive diagnostic procedures. Secondary – the higher efficacy of treatment with its influence on improving patients’ overall survival and the specific mechanism of action of drugs used in systemic therapy lead to growing population of men suffering from prostate cancer in general and, specifically – patients with castration resistance. It is hormone therapy to play the key role in systemic treatment of prostate cancer with increasing significance of novel drugs focused on inhibition of molecular signal transduction mediated by androgen receptor. Abiraterone acetate is the representative of this therapeutic class. The paper describes the most clinically relevant data regarding the drug.
    Źródło:
    OncoReview; 2021, 11, 3; 80-84
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    The role of enzalutamide in the treatment of prostate cancer from the perspective of Polish oncologists
    Autorzy:
    Bal, Wiesław
    Gajda, Maksymilian
    Powiązania:
    https://bibliotekanauki.pl/articles/2159010.pdf
    Data publikacji:
    2022-06-30
    Wydawca:
    Medical Education
    Tematy:
    enzalutamide
    prostate cancer
    hormonotherapy
    anti-androgen
    second-generation an-
    Opis:
    For several years, prostate cancer has remained the most common malignancy in male patients in Poland. A large number of patients combined with rising costs of therapy translate into a significant socio-economic burden. In a clinical oncologist’s practice, we usually deal with patients with advanced prostate cancer. Taking into account the poorer prognosis in advanced disease, development of new therapeutic options as well we their adequate selection is of paramount importance. Enzalutamide is one of the second-generation androgen axis inhibitors, which has the ability to overcome resistance to androgen deprivation therapy by inhibiting the androgen-DNA signalling on several levels. Its efficacy and safety had been proven in numerous phase II and phase III clinical studies and it has been registered by regulatory authorities in the United States and European Union in the treatment of mCRPC, mCSPC and nmCRPC. In this article selected issues related to the treatment of prostate cancer are discussed, with particular emphasis on the role of enzalutamide (including its mechanism of action, indications, efficacy and safety).
    Źródło:
    OncoReview; 2022, 12, 2; 45-49
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Prostate cancer in clinical practice. First experiences with apalutamide within the context of therapeutic program B.56
    Autorzy:
    Trzebiński, Krzysztof
    Powiązania:
    https://bibliotekanauki.pl/articles/22676841.pdf
    Data publikacji:
    2023-04-01
    Wydawca:
    Medical Education
    Tematy:
    non-metastatic castration-resistant prostate cancer
    apalutamide
    androgen receptor inhibitor
    Opis:
    The article contains a case report of patient diagnosed with castration-resistant non-metastatic prostate cancer, treated with a novel androgen receptor inhibitor – apalutamide.
    Źródło:
    OncoReview; 2023, 13, 1; 27-30
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Apalutamid for treatment of nonmetastatic castration-resistant prostate cancer - case study
    Autorzy:
    Sikora-Kupis, Bożena
    Powiązania:
    https://bibliotekanauki.pl/articles/22676707.pdf
    Data publikacji:
    2023-03-31
    Wydawca:
    Medical Education
    Tematy:
    non-metastatic castration-resistant prostate cancer
    nmCRPC
    androgen receptor targeted agents
    ARTA
    apalutamide
    darolutamide
    enzalutamide
    Opis:
    A special form of prostate cancer is non-metastatic castration-resistant prostate cancer. Patients with this form have rising prostate-specific antigen and castrate testosterone levels, with no radiological findings of metastatic disease on computed tomography and bone scan. The phase III trials demonstrated apalutamide, darolutamide or enzalutamide to be associated with a significantly longer median metastasis-free survival. The featured description presents one case of man with non-metastatic castration-resistant prostate cancer who was treated with apalutamide.
    Źródło:
    OncoReview; 2023, 13, 1; 6-8
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
      Wyświetlanie 1-15 z 15

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies